Drugs / TASIDOTIN
TASIDOTIN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00078455 | Dec 2003 → Aug 2005 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00068211 | Aug 2003 → Jan 2006 | melanoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00082134 | ? → Dec 2005 | hormone-resistant prostate carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TASIDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111109 ↗ |
| Known as | ILX651 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00068211 ↗ |
| Known as | TASIDOTIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111109 ↗ |
| Known as | Tasidotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111109 ↗ |
| Known as | Tasidotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111109 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2111109 ↗ |
| Route | Intravenous | “ILX651 administered IV daily for 5 consecutive days once every 21 days.” NCT00068211 ↗ |